From: Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer
MiRNAs | Tumor suppressor (−)/tumor promotor (+) | Cell lines | Targets | Mechanisms of regulation | |
---|---|---|---|---|---|
MiR-326 [142] | – | MCF-7, MDA-MB-468 | TAZ | Circular RNA 0000511 can eliminate the anti-tumor effect of miR-326 by upregulating TAZ | |
MiR-146b [143] | – | MCF-7 | p-YAP | The process of MUC19 reducing YAP phosphorylation is inhibited by miR-146b | |
MiR-199a-3p [133] | – | MDA-MB-231 | LATS1, YAP1 | miR-199a-3p suppresses YAP1 and upregulates LATS1 | |
MiR-574-5p [135] | – | MDA-MB-231, T47D | TAZ | miR-574-5p targets Sox2 to suppress TAZ | |
MiR-1297 [144] | – | MDA-MB-231, MDA-MB-468 | TAZ | miR-1297 inhibits TAZ | |
– | MDA-MB-468, BT549, tamoxifen resistant MCF7 | TAZ | miR-125a-5p directly inhibits TAZ expression. Downregulation of CYTOR decreases protein and mRNA levels of TAZ in tamoxifen resistant MCF7 cells, which is rescued by miR-125a-5p suppression | ||
MiR-515-5p [147] | + | MDA-MB-231, MDA-MB-453 | YAP, TAZ, p-TAZ | Knockdown LINC00673 reduces the level of YAP/TAZ and increases p-YAP through miR-515-5p inactivation | |
MiR-591 [148] | – | MCF-7, SKBR3 | YAP, LATS | miR-591 inhibits YAP and upregulates LATS | |
MiR-520b [94] | + | MCF-7, MDA-MB-231 | LATS2, p-YAP, YAP | miR-520b promotes migration activity and stemness of breast cancer, which can be abolished by overexpression of LATS2. miR-520b upregulates nuclear YAP and inhibits LATS2 as well as p-YAP | |
MiR-372 [149] | + | MCF-7, MDA-MB-231 | LATS2 | miR-372 inhibits LATS2 | |
MiR-18a [150] | − | Trastuzumab-resistant SKBR-3 | YAP1 | miR-18a directly inhibits YAP1 | |
MiR-424 [151] | − | MDA-MB-231, HCC-1937 | YAP | miR-424 inhibits YAP | |
MiR-205 [134] | − | SUM159 | TAZ | miR-205 inhibits TAZ, which is involved in the mammospheres formation and BCSC renewal | |
MiR-135b [152] | + | MDA-MB-231, MCF-7, 293 T | LATS2, | miR-135b inhibits LATS2 | |
MiR-506 [153] | – | MDA-MB-231 | YAP | miR-506 inhibits YAP | |
MiR-31 [154] | + | MDA-MB-231 | LATS2 | miR-31 inhibits LATS2 | |
MiR-93 [155] | + | MT-1 | LATS2 | miR-93 inhibits LATS2 |